NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside an auto-regulation platform, has announced the online publication of three abstracts submitted to the American Society of Haematology Annual meeting, to be held December 10-13, 2022.
Read the full story from NovalGen here.
We make UCL’s research physical and life sciences ideas happen.
